Fabrizio Stocchi
Overview
Explore the profile of Fabrizio Stocchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
6063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salamone E, Carpi M, Noce G, Percio C, Lopez S, Lizio R, et al.
Clin Neurophysiol
. 2025 Feb;
171:164-181.
PMID: 39914158
Objectives: Alzheimer's disease patients with mild cognitive impairment (ADMCI) show abnormal resting-state eyes-closed electroencephalographic (rsEEG) alpha rhythms (8-12 Hz) and may suffer from daytime sleepiness. Our exploratory study tested the...
2.
Ellenbogen A, Poewe W, Espay A, Simuni T, Gurevich T, Yardeni T, et al.
Parkinsonism Relat Disord
. 2025 Jan;
132:107293.
PMID: 39884033
Introduction: ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study...
3.
Percio C, Lizio R, Lopez S, Noce G, Jakhar D, Carpi M, et al.
Neurobiol Dis
. 2025 Jan;
206:106807.
PMID: 39855475
Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) are more prevalent in males than females. Furthermore, they typically showed abnormally high delta (< 4 Hz) and low...
4.
Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma R, et al.
Parkinsonism Relat Disord
. 2025 Jan;
132:107257.
PMID: 39798255
Introduction: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in...
5.
Percio C, Lizio R, Lopez S, Noce G, Carpi M, Jakhar D, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796211
Patients with mild cognitive impairment due to Alzheimer's disease (ADMCI) typically show abnormally high delta (<4 Hz) and low alpha (8-12 Hz) rhythms measured from resting-state eyes-closed electroencephalographic (rsEEG) activity....
6.
Ferreira J, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernandez G, et al.
Eur J Neurol
. 2025 Jan;
32(1):e16420.
PMID: 39790009
Background: Catechol-O-methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa-treated patients without...
7.
Stocchi F, Bravi D, Emmi A, Antonini A
Nat Rev Neurol
. 2024 Nov;
20(12):695-707.
PMID: 39496848
Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we...
8.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al.
Nat Med
. 2024 Oct;
30(12):3669-3675.
PMID: 39379705
The Phase II trial of Anti-alpha-Synuclein Antibody in Early Parkinson's Disease (PASADENA) is an ongoing double-blind, placebo-controlled trial evaluating the safety and efficacy of prasinezumab in early-stage Parkinson's disease (PD)....
9.
Ferreira J, Lee J, Ma H, Jeon B, Poewe W, Antonini A, et al.
J Neurol
. 2024 Aug;
271(10):6729-6738.
PMID: 39164557
Background: The wearing-off phenomenon is a key driver of medication change for patients with Parkinson's disease (PD) treated with levodopa. Common first-line options include increasing the levodopa dose or adding...
10.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...